TRIAL OF IMMEDIATE/DEFERRED IDV PLUS ANTIRETROVIRAL THERAPY IN HIV+ ADULTS

对成人 HIV 患者进行立即/延期 IDV 加抗逆转录病毒治疗的试验

• 批准号: 6282266
• 负责人: CHERYL L BESCH
• 金额: $ 1.97万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1999-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6282266
• 关键词: AIDS therapy; HIV infections; antiAIDS agent; antiviral agents; clinical research; clinical trial phase I; human subject; human therapy evaluation; protease inhibitor; virus RNA; virus load

The purpose of this study is to evaluate the effect of immediate versus deferred Indinavir (IDV) in addition to background antiretroviral therapy on disease progression or death in patients with CD4+ cell counts between 200 and 500 cells/mm3 and plasma HIV RNA levels greater than or equal to 10,000 copies/mL.

本研究的目的是评估立即与 除了背景抗逆转录病毒药物外，还需要延迟印地那韦 (IDV) 对 CD4+ 细胞计数患者疾病进展或死亡的治疗 200 至 500 个细胞/mm3 且血浆 HIV RNA 水平大于或 等于 10,000 拷贝/mL。